Cargando…

Reducing carbon footprint by switching to reusable soft-mist inhalers

OBJECTIVE: Inhalation therapy is the cornerstone of COPD, together with non-pharmacological treatments. Long-acting muscarinic antagonists (LAMAs), alone or in combination with long-acting β-agonists (LABAs), are commonly used. Pressurised metered-dose inhalers (pMDIs), dry powder inhalers (DPIs) an...

Descripción completa

Detalles Bibliográficos
Autores principales:	Janson, Christer, Hernando Platz, Jaime, Soulard, Stéphane, Langham, Sue, Nicholson, Lindsay, Hartgers-Gubbels, Elisabeth Sophia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	European Respiratory Society 2023
Materias:	Original research articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10152248/ https://www.ncbi.nlm.nih.gov/pubmed/37143844 http://dx.doi.org/10.1183/23120541.00543-2022

Ejemplares similares

Reduced Environmental Impact of the Reusable Respimat(®) Soft Mist™ Inhaler Compared with Pressurised Metered-Dose Inhalers
por: Hänsel, Michaela, et al.
Publicado: (2019)

Use of Respimat(®) Soft Mist™ Inhaler in COPD patients
por: Anderson, Paula
Publicado: (2006)

Asthma patients prefer Respimat(®) Soft Mist™ Inhaler to Turbuhaler(®)
por: Hodder, Rick, et al.
Publicado: (2009)

Impact of health technology assessment on prescribing patterns of inhaled fixed-dose combination triple therapy in chronic obstructive pulmonary disease
por: Cook, Jennifer, et al.
Publicado: (2021)

The Respimat(®) Soft Mist Inhaler: Implications of Drug Delivery Characteristics for Patients
por: Iwanaga, Takashi, et al.
Publicado: (2019)

Carbon footprint impact of the choice of inhalers for asthma and COPD
por: Janson, Christer, et al.
Publicado: (2020)

Development of Respimat(®) Soft Mist™ Inhaler and its clinical utility in respiratory disorders
por: Dalby, Richard N, et al.
Publicado: (2011)

Patient preferences for inhaler devices in chronic obstructive pulmonary disease: experience with Respimat(®) Soft Mist(™) Inhaler
por: Hodder, Richard, et al.
Publicado: (2009)

Inhaler usability of a pressurized metered dose inhaler and a soft mist inhaler in patients with COPD: A simulated-use study
por: Ding, Bo, et al.
Publicado: (2018)

Lack of paradoxical bronchoconstriction after administration of tiotropium via Respimat(®) Soft Mist™ Inhaler in COPD
por: Hodder, Rick, et al.
Publicado: (2011)

Assessment of inhalation flow patterns of soft mist inhaler co-prescribed with dry powder inhaler using inspiratory flow meter for multi inhalation devices
por: Hira, Daiki, et al.
Publicado: (2018)

Pharmacokinetics and tolerability (Study 1) with particular reference to ocular safety (Study 2) of tiotropium Respimat(®) Soft Mist(™) Inhaler: findings from two dose-ranging studies in healthy men
por: Feifel, Ulrich, et al.
Publicado: (2008)

Costs and Clinical Consequences of Compliance with COPD GOLD Recommendations or National Guidelines Compared with Current Clinical Practice in Belgium, Germany, Sweden, and the United States
por: Sethi, Sanjay, et al.
Publicado: (2022)

Efficiency of Ipratropium Bromide and Albuterol Deposition in the Lung Delivered via a Soft Mist Inhaler or Chlorofluorocarbon Metered‐Dose Inhaler
por: MacGregor, TR, et al.
Publicado: (2016)

Pharmacokinetics and safety of olodaterol administered with the Respimat Soft Mist inhaler in subjects with impaired hepatic or renal function
por: Kunz, Christina, et al.
Publicado: (2016)

Long-term safety of tiotropium delivered by Respimat(®) SoftMist™ Inhaler: patient selection and special considerations
por: Tan, Ching Kuo, et al.
Publicado: (2016)

Device use errors with soft mist inhalers: A global systematic literature review and meta-analysis
por: Navaie, Maryam, et al.
Publicado: (2020)

Patient perceptions of the re-usable Respimat(®) Soft Mist™ inhaler in current users and those switching to the device: A real-world, non-interventional COPD study
por: Dreher, Michael, et al.
Publicado: (2021)

Higher lung deposition with Respimat(®) Soft Mist(™) Inhaler than HFA-MDI in COPD patients with poor technique
por: Brand, Peter, et al.
Publicado: (2008)

A Handling Study to Assess Use of the Respimat(®) Soft Mist™ Inhaler in Children Under 5 Years Old
por: Kamin, Wolfgang, et al.
Publicado: (2015)

Technical Evaluation of Soft Mist Inhaler Use in Patients with Chronic Obstructive Pulmonary Disease: A Cross-Sectional Study
por: Zhang, Wei, et al.
Publicado: (2020)

Pharmacokinetic Study of Epinephrine Hydrofluoroalkane (Primatene MIST) Metered-Dose Inhaler
por: Kerwin, Edward M., et al.
Publicado: (2020)

A dose-ranging study of tiotropium delivered via Respimat(®) Soft Mist(TM) Inhaler or HandiHaler(®) in COPD patients
por: Caillaud, Denis, et al.
Publicado: (2007)

Instant velocity and consistency of emitted cloud change by the different levels of canister filling with Metered Dose Inhalers (MDIs), but not with Soft Mist Inhalers (SMIs): a bench study
por: Dal Negro, Roberto W., et al.
Publicado: (2017)

Early Effects of Low Molecular Weight Heparin Therapy with Soft-Mist Inhaler for COVID-19-Induced Hypoxemia: A Phase IIb Trial
por: Erelel, Mustafa, et al.
Publicado: (2021)

Night of the Mist
por: Colwell, Catherine
Publicado: (1960)

Effects of switching from a metered dose inhaler to a dry powder inhaler on climate emissions and asthma control: post-hoc analysis
por: Woodcock, Ashley, et al.
Publicado: (2022)

Treatment with inhaled corticosteroids in chronic obstructive pulmonary disease
por: Janson, Christer
Publicado: (2020)

TRONARTO: A Randomized, Placebo-Controlled Study of Tiotropium/Olodaterol Delivered via Soft Mist Inhaler in COPD Patients Stratified by Peak Inspiratory Flow
por: Mahler, Donald A, et al.
Publicado: (2021)

Healthcare Resource Utilization, Exacerbations, and Readmissions Among Medicare Patients with Chronic Obstructive Pulmonary Disease After Long-Acting Muscarinic Antagonist Therapy Initiation with Soft Mist versus Dry Powder Inhalers
por: Singer, David, et al.
Publicado: (2020)

Value Insider Season 1 Episode 1: The Importance of Payers and HTA: How Did We End Up Here? (Introduction to Value) [Podcast]
por: Drummond, Michael F, et al.
Publicado: (2022)

Value Insider Season 1 Episode 5: What Other Aspects of Value May Be Relevant? (Societal Impact) [Podcast]
por: Garrison, Louis P, et al.
Publicado: (2022)

Value Insider Season 1 Episode 2: How to Measure Quality of Life and Utility? (QoL) [Podcast]
por: Devlin, Nancy J, et al.
Publicado: (2022)

Value Insider Season 1 Episode 3: How Does Budget Impact and Affordability in Healthcare Work? (BI and Affordability) [Podcast]
por: Sullivan, Sean D, et al.
Publicado: (2022)

Value Insider Season 1 Episode 6: How Will Market Access and Value Demonstration Evolve? (Future Outlook) [Podcast]
por: Kanavos, Panos G, et al.
Publicado: (2022)

Wing Patterns in the Mist
por: Martin, Arnaud, et al.
Publicado: (2010)

The CERN version of MIST
por: McCarroll, S J
Publicado: (1963)

The Cholera Mist Again
Publicado: (1866)

Dust, Mist and Clouds
Publicado: (1883)

Effect of Tiotropium Soft Mist Inhalers on Dynamic Changes in Lung Mechanics of Patients with Chronic Obstructive Pulmonary Disease Receiving Mechanical Ventilation: A Prospective Pilot Study
por: Fu, Pin-Kuei, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_4vktcrijkpgab7tt5hjivcso4l